Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.


TSX:HLS - Post by User

Bullboard Posts
Post by valueinvestorron Mar 01, 2012 3:19pm
151 Views
Post# 19613006

2011 results

2011 results

AJAX, ONTARIO, Mar 01, 2012 (MARKETWIRE via COMTEX) -- Automodular Corporation CA:AM+0.74%("Automodular") reports net earnings of $12.2 million or
.61 per share for the year ended December 31, 2011 compared to net earnings of $4.8 million or
.21 per share in 2010. Comparative results have been restated to reflect the transition to International Financial Reporting Standards.

Automodular's consolidated financial statements, management discussion and analysis and annual information form for the year ended December 31, 2011 will be filed on SEDAR on or about March 7, 2012 and the complete annual report together with the management information circular and proxy will be mailed to shareholders on or about April 27, 2012.

Automodular enters the 2012 year with a strong balance sheet and cash on hand of $14.8 million. Automodular continues to seek out diversification opportunities that will leverage the skill sets of its existing personnel.

Bullboard Posts